Myricx Bio

WELCOME: Following our £90m ($114m) Series A financing, we are delighted to welcome Lucille Conroy, Principal at our new investor Abingworth, to our board. The ADC area is one of the most promising modalities and new payloads are urgently needed. The series A funds enable us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. As an investment manager within a leading and highly experienced venture group, we look forward to Lucille’s contribution to our strategy to deliver life changing treatments to patients. She joins board members - Chris Martin (independent chair), Robin Carr (CEO), Maina Bhaman, Partner at Sofinnova Partners, Jonathan Tobin, Partner at Brandon Capital and Michael Bauer, Ph.D., Partner in the Venture Investments group at Novo Holdings. #appointment #drugdevelopment #UKbiotech

WELCOME: Following our £90m ($114m) Series A financing, we are delighted to welcome Michael Bauer, Ph.D., Partner in the Venture Investments group at our new investor Novo Holdings, to our board. The series A funds enable us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. The ADC area is one of the most promising modalities and new payloads are urgently needed. As a seasoned investment manager within the venture investments group of a major pharma, we look forward to Michael’s contribution to our strategy to deliver life changing treatments to patients. He joins board members - Chris Martin (independent chair), Robin Carr (CEO), Maina Bhaman, Partner at Sofinnova Partners, Jonathan Tobin, Partner at Brandon Capital and Lucille Conroy, Principal at Abingworth. #appointment #drugdevelopment #UKbiotech

READ - the story of our history. Brilliant insights and innovation by our founding team Ed Tate Andy Bell and Roberto Solari. Excellent support and teamwork from our founding investors Brandon Capital and Sofinnova Partners. Thank you CRUK for supporting our journey. Exciting times ahead. #teamwork #innovation #resilience

BOARD CHANGES: Following our £90m ($114m) series A financing, we are pleased to announce the following board changes. Dr Rachael Brake has stepped down as an independent Non-Executive Director. She joined us in 2022 and has made a tremendous contribution to the company through our transformative evolution both within and outside of board meetings. Thank you. Co-founder Professor Ed Tate has stepped down as Director but remains a Board Observer and closely involved with the company as a N-Myristoyltransferase (#NMT) key opinion leader and Scientific Advisor to the company. Michael Karl Bauer from Novo Holdings and Lucille Conroy from Abingworth have joined the Myricx’ Board as Investor Directors. Other board directors are Chris Martin, Independent Chair, Robin Carr, CEO, and Maina Bhaman from Sofinnova Partners and Jonathan Tobin from Brandon Capital as Investor Directors. We look forward to working together to execute on our strategy to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. Read the full release HERE https://lnkd.in/evhq7mVD #appointment #drugdevelopment #UKbiotech #ADC

It was a pleasure meeting BiotechTV new European correspondent Amy Brown and explaining our excitement around the prospects for our #NMTi-ADCs. Great to be financed to take two programs into the clinic and further develop our NMTi payload platform.

FUNDING NEWS: We are thrilled to announce our £90m ($114m) series A financing, one of the largest biotech series A in European biotech and the largest in the UK this year. The round was co-led by new investors Novo Holdings and Abingworth. Additional new investors British Patient Capital, Cancer Research Horizons and Eli Lilly and Company also participated alongside founding investors Brandon Capital and Sofinnova Partners. The series A funds enable us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. The ADC area is one of the most promising modalities and new payloads are urgently needed. Having been a virtual company since spinning out from Imperial College London and The Francis Crick Institute, we will now move to establish laboratory operations in London’s biotech hub and will be expanding our management and R&D teams. Welcome to our new investors and thank you to everyone that has contributed to the progress of the company so far, not least our founding scientists Ed Tate, Roberto Solari and Andy Bell. Exciting times ahead. Read the full release HERE https://lnkd.in/eSu9mP3c #venturecapital #financing #drugdevelopment #UKbiotech

🎉 #BIAmember Brandon Capital today announced the launch of their sixth fund with a $270 million initial close to drive #LifeScience innovation ➡️ https://ow.ly/u0QS50S89Kn The new #Fund will support the growth of 🌏 #Australian and #NewZealand #LifeSciences startups, invest in scale-ups, and expand Brandon Capital’s international presence, particularly in the 📍 #UK, #Europe, and the #USA 🚀 More information in the link above 👆

Our CSO, Francesca Zammarchi, is speaking about our novel NMTi payload platform and pre-clinical efficacy studies for our lead ADCs at the ADC Payload Summit, Boston, MA on May 22nd at 12.30pm.  #drugdiscovery #oncology #cancer  #antibodydrugconjugates

Myricx’s Co-founder and SAB Chair, Prof Ed Tate, has recently published a peer-reviewed article in Nature Reviews Cancer: Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets.     The article provides an overview of the significance of protein lipidation in cancer, and outlines how targeting these pathways, including N-Myristoylation, offers promising new approaches for #cancer treatments.   Myricx Bio is developing these insights on inhibiting protein lipidation into its pipeline of next-generation ADCs based on NMT inhibition. View the publication: https://lnkd.in/eyG4FDZq   #oncology #ADC #antibody #drugdiscovery #UKbiotech

For February 4th #WorldCancerDay, we want to help raise awareness about the importance of developing new safer and more effective treatments for cancer patients, and how we are playing a part towards creating a cancer-free world.    At Myricx, we are working hard to develop a completely novel class of payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (#NMT) for the treatment of cancer.    Find out more about our pipeline of NMTi-ADCs based on clinically-validated targets: https://lnkd.in/efhjhsm5   #CloseTheCareGap #oncology #cancer #drugdiscovery #antibodydrugconjugates #ADC #WCD24